The list below contains links to the European Medicines Agency. Through this website, you will find links to the European Public Assessment Report (EPAR) as well as the Patient Information Leaflets (PIL) and Summary of Product Characteristics (SPC) for our licensed product Translarna▼ (ataluren) .

Please note that this information is not intended to replace the advice of a qualified healthcare professional.

Translarna (ataluren)


Translarn (ataluren)


▼ This medicinal product is subject to additional monitoring. Adverse Events should be reported. Reporting forms and information can be found at or email

Adverse events should also be reported to PTC Therapeutics Ltd at

By following this link you will be leaving the website.

Please note that PTC Therapeutics International Limited does not take responsibility for the content displayed on other websites.
Cancel Continue